Yinhu Qingwen Decoction for the Treatment of Mild / Common CoVID-19
Status:
Suspended
Trial end date:
2023-05-01
Target enrollment:
Participant gender:
Summary
In December 2019, Wuhan, in Hubei province, China, became the center of an outbreak of
pneumonia caused by CoVID-19, and the number of cases of infection with CoVID-19 identified
in Wuhan increased markedly over the later part of January 2020, with cases identified in
multiple other Provinces of China and internationally.
Given no specific antiviral therapy for CoVID-19 infection and the availability of Yinhu
Qingwen Decoction as a potential antiviral Chinese medicine based on vivo antiviral studies
in CoVID-19, this randomized,three-arm controlled, single-blind trial will evaluate the
efficacy and safety of Yinhu Qingwen Decoction (Granula) in patients hospitalized with mild
or common CoVID-19 respiratory disease.